The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
IBI363 (TAK-928) plus chemotherapy as first-line (1L) treatment for advanced non–small cell lung cancer (NSCLC).
 
Hai-Yan Tu
No Relationships to Disclose
 
Yong Wang
No Relationships to Disclose
 
Hongxu Liu
No Relationships to Disclose
 
Dingzhi Huang
No Relationships to Disclose
 
Pei-Rong Ren
No Relationships to Disclose
 
Fangling Ning
No Relationships to Disclose
 
Xi Shi
No Relationships to Disclose
 
Baogang Liu
No Relationships to Disclose
 
Haiyan Yang
No Relationships to Disclose
 
Lifeng Wang
No Relationships to Disclose
 
Huijing Feng
No Relationships to Disclose
 
Chunling Liu
No Relationships to Disclose
 
Xian Zhong
No Relationships to Disclose
 
Minghui Zhang
No Relationships to Disclose
 
Yuping Sun
No Relationships to Disclose
 
Aiqin Gao
No Relationships to Disclose
 
Sujie Zhang
Employment - Innovent Biologics
 
Jiaying Du
Employment - Innovent Biologics
 
Jiawei Ye
Employment - Innovent Biologics
 
Yi-Long Wu
Honoraria - AstraZeneca; BeiGene Beijing; Boehringer Ingelheim; Bristol-Myers Squibb/China; Hengrui Pharmaceutical; MSD Oncology; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Roche; Takeda
Research Funding - BMS (Inst); Boehringer Ingelheim (Inst); Pfizer (Inst); Roche (Inst)